BioMarin reported Q4 2025 total revenues of USD 875 million (+17%) and FY 2025 total revenues of USD 3.22 billion (+13%), led by Enzyme Therapies revenue of USD 549 million in Q4 (+13%) and USD 2.11 billion in FY (+9%), and VOXZOGO revenue of USD 273 million in Q4 (+31%) and USD 927 million in FY (+26%). Q4 GAAP net loss was USD 47 million, while FY GAAP net income was USD 349 million; Q4 results reflected charges of about USD 240 million tied to BioMarin’s decision to voluntarily withdraw ROCTAVIAN from the market, including a USD 119 million inventory write-off and USD 118 million of long-lived asset impairments. Q4 non-GAAP income was USD 89 million and FY non-GAAP income was USD 614 million. Operating cash flow was USD 100 million in Q4 and USD 828 million in FY, with cash and investments of about USD 2 billion at year-end. BioMarin highlighted the planned acquisition of Amicus Therapeutics, expected to close in Q2 2026, adding Galafold (Fabry disease) and Pombiliti plus Opfolda (Pompe disease), and said it secured about USD 3.7 billion of non-convertible debt financing to support the deal. For 2026 (excluding any post-close Amicus contribution), BioMarin guided total revenues of USD 3.33 billion to USD 3.43 billion and non-GAAP diluted EPS of USD 4.95 to USD 5.15, and said it expects non-GAAP operating margin of about 40%. Pipeline updates included Phase 3 hypochondroplasia data for VOXZOGO in H1 2026 and a U.S. sNDA for full approval in achondroplasia in Q2 2026, initiation of a registration-enabling Phase 2/3 study for BMN 333 in H1 2026, and a U.S. PDUFA date of February 28, 2026 for a PALYNZIQ adolescent label expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF92924) on February 23, 2026, and is solely responsible for the information contained therein.